Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2A Study of PF-07104091 as Monotherapy and in Combination in Advanced Solid Tumors
2022-001679-15Phase 2Active
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegtociclib in breast cancer, triple-negative breast cancer (TNBC), ovarian cancer and 2 more (4 arms), sponsored by Pfizer. Primary endpoint: Primary endpoints (Part 1A, Part 1B, Part 1C). Started Aug 2022; status: active.
02
Drugs
tegtociclib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)ovarian cancersmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001679-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001679-15.